コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 oba), and bone marrow supporting agents (eg, erythropoietin).
2 response to hypoxia, including production of erythropoietin.
3 pted in 9 patients due to anemia; 4 received erythropoietin.
4 s to demonstrate the functional existence of erythropoietin.
5 ed basal expression and hypoxic induction of erythropoietin.
6 tely quantify relative sialylation levels of Erythropoietin.
7 throblasts through a mechanism distinct from erythropoietin.
8 nd an indirect relation that was mediated by erythropoietin.
9 ally significant dimension to the biology of erythropoietin.
10 significantly elevated levels of circulating erythropoietin.
11 tion, often caused by impaired production of erythropoietin.
12 er injection, a time course similar to serum erythropoietin.
13 is produced by erythroblasts in response to erythropoietin.
14 gene circuit for the on-demand secretion of erythropoietin.
15 nd 3 level III studies) evaluated the use of erythropoietin.
16 luded the presence of hemoglobinopathies and erythropoietin.
17 moglobin levels and appropriate increases in erythropoietin.
18 ls), along with a poor response to exogenous erythropoietin.
19 ex difference in mouse metabolic response to erythropoietin.
20 ndomly assigned to receive recombinant human erythropoietin (3000 IU/kg; n=256) or placebo (n=239) in
22 as determined by suppression of circulating erythropoietin, a HIF-2 target and possible pharmacodyna
23 et gene characterized was EPO, which encodes erythropoietin-a glycoprotein hormone that controls eryt
26 on of granulocyte colony-stimulating factor, erythropoietin, aminocaproic acid, and phytonadione was
31 he EPOR dimer in the presence and absence of erythropoietin and a series of agonistic or antagonistic
32 show that cigarette smoke exposure increases erythropoietin and bone marrow-derived erythroferrone an
33 hropoiesis-stimulating agents (ESAs) such as erythropoietin and darbepoetin in preterm and term infan
34 t to promote oxygen delivery (by stimulating erythropoietin and erythrocytosis) and decrease oxygen c
35 its name: (1) telangiectasias; (2) elevated erythropoietin and erythrocytosis; (3) monoclonal gammop
40 SnPP administration led to a decrease in erythropoietin and increase in hepcidin serum levels, ch
44 ternal 25(OH)D was inversely associated with erythropoietin at both midgestation (P <0.05) and delive
47 include anaemia due to reduced production of erythropoietin by the kidney; reduced red blood cell sur
50 ood cell units per 8 weeks); pre-study serum erythropoietin concentration (<200 IU/L, 200-500 IU/L, a
52 data reveal a possible correlation of higher erythropoietin concentrations in the blood and in the ey
53 ly lower than those in the recombinant human erythropoietin control arm in the hemodialysis study, an
55 CT to evaluate whether priming of ECFCs with erythropoietin could enhance their homing to the ischemi
56 Although the most common cause is relative erythropoietin deficiency, other factors such as reduced
57 genitors delays G1-S progression and arrests erythropoietin-dependent cell growth while favoring term
61 is produced by erythroblasts in response to erythropoietin (EPO) and acts in the liver to prevent he
64 essential mediators of red cell production, erythropoietin (EPO) and its cell surface receptor (EPO
65 dimeric receptor-ligand system, the cytokine Erythropoietin (EPO) and its receptor (EpoR), to dimeriz
69 to estimate time trends in hemoglobin (Hgb), erythropoietin (EPO) dose, intravenous (IV) iron dose, f
70 hd2, and Phd3 (Phd(1/2/3)hKO) promoted liver erythropoietin (EPO) expression 1246-fold, whereas renal
71 s adjusted for these factors were run, three erythropoietin (EPO) genetic variants in linkage disequi
90 asts number, reduces apoptosis, and enhances erythropoietin (Epo) levels in controls, but not in Tfr2
92 ction induced anemia, splenomegaly, elevated erythropoietin (EPO) levels, and extramedullary erythrop
100 nally, all S-HB had increased phosphorylated erythropoietin (EPO) receptor and phosphorylated STAT-5
103 fish, murine, and human models, we show that erythropoietin (EPO) signaling, together with the GATA1
104 deficiency and higher circulating levels of erythropoietin (EPO) stimulate the expression and concom
108 T lymphocytes could be rendered sensitive to erythropoietin (Epo) through ectopic expression of its w
109 sly reported that the topical application of erythropoietin (EPO) to cutaneous wounds in rats and mic
110 when erythropoiesis is acutely stimulated by erythropoietin (EPO) to favor iron supply to maturing er
112 ia-inducible factor 1-alpha (HIF-1alpha) and erythropoietin (EPO) were measured as potential mechanis
114 in erythropoiesis and is the main source of erythropoietin (EPO), an oxygen-sensitive glycoprotein t
115 am proteins, glucose transporter 1 (GLUT-1), erythropoietin (EPO), and vascular endothelial growth fa
116 ond-Blackfan anaemia, are not treatable with erythropoietin (Epo), because the colony-forming unit er
117 ied this approach in vivo to the anemia drug erythropoietin (EPO), to direct its activity to EPO rece
119 reached the kidney and reduced expression of erythropoietin (Epo), which we identified as a MIR122 ta
122 ated that low reticulocytosis and suppressed erythropoietin (Epo)-induced erythropoiesis are features
130 tides [ASOs]) or increase erythropoiesis (by erythropoietin [EPO] administration or modulating the ab
131 ive of the stress-induced (hemolytic or post-erythropoietin [Epo]) treatment, only native CD11b(lo) s
133 red; this was accompanied by increased renal erythropoietin expression and stabilization of hypoxia-i
134 derlying mechanism is suppression of hepatic erythropoietin expression associated with the downregula
136 G cells, angiotensin II negatively regulated erythropoietin expression in the transformed cells.
138 s of the kidney suppresses renin and induces erythropoietin expression, this study aimed to character
139 um bilirubin, reticulocyte counts, and serum erythropoietin following intestinal HIF-2alpha disruptio
140 lysis study; continuing on recombinant human erythropoietin for the hemodialysis study) for 4 weeks,
141 revention of contrast-induced AKI and use of erythropoietin for the prevention of AKI, two therapeuti
142 ndard used in real-time PCR assays for human erythropoietin gene, cDNA or transcript, we found that i
143 k-in mutation results in upregulation of the erythropoietin gene, erythrocytosis, and augmented hypox
144 re was no significant difference between the erythropoietin group and the placebo group in the incide
145 34/89 [38.2%; 95% CI, 28.1% to 49.1%]), both erythropoietin groups were futile (first dosing regimen:
147 fewer infants treated with recombinant human erythropoietin had abnormal scores for white matter inju
151 HO-K1 cells co-expressing arginase and human erythropoietin (hEPO), which also displayed stable expre
153 irin dose in 29% of the patients, the use of erythropoietin in 54%, and blood transfusions in 12%.
154 t, we have recently shown that expression of erythropoietin in a GnTI knock-out, FUT8-overexpressing
156 supported human cells engineered to secrete erythropoietin in immunocompetent mice, as well as trans
158 1 induced hypermethylation and repression of erythropoietin in pericytes; these effects were prevente
160 ntiation pathway of humans, and implicate an erythropoietin-independent, macrophage-associated pathwa
161 lts identify EphB4 as a critical mediator of erythropoietin-induced tumor progression and further pro
162 light perception (NLP) despite prescribed IV erythropoietin injections 20,000 units daily for 3 days
163 ignaling, while preventing responsiveness to erythropoietin-instigated signals that promote different
164 omatin and abrogates hepcidin suppression by erythropoietin, iron deficiency, thalassemia, and hemoch
165 fold greater risk of anemia, suggesting that erythropoietin is a sensitive predictor of anemia at del
166 patients with heart failure (HF), high serum erythropoietin is associated with risk of recurrent HF a
167 date the mechanisms through which endogenous erythropoietin levels associate with specific outcomes.
168 ased accompanied by increased HIF-1alpha and erythropoietin levels in the kidneys of KS-tg/OVE mice.
169 heparanase and TF procoagulant activity, and erythropoietin levels were found in the plasma of 67 tha
171 have evaluated the association of endogenous erythropoietin levels with clinical outcomes in the comm
172 red blood cell [RBC] count despite elevated erythropoietin levels), along with a poor response to ex
174 nomegaly, and bone pathology, while reducing erythropoietin levels, improving erythrocyte morphology,
178 s unexpected for a JAK1/2 inhibitor, because erythropoietin-mediated JAK2 signaling is essential for
182 Randomized clinical trial of 200 patients (erythropoietin, n = 102; placebo, n = 98) with closed he
183 a nonrandomized subset of 165 infants (n=77 erythropoietin; n=88 placebo), brain abnormalities were
185 dialysis and not receiving recombinant human erythropoietin (nondialysis study) and in patients with
186 d head injury, neither the administration of erythropoietin nor maintaining hemoglobin concentration
187 ossible influence of serum concentrations of erythropoietin on the development of diabetic retinopath
188 e is limited information about the effect of erythropoietin or a high hemoglobin transfusion threshol
190 s to 27 weeks 6 days of gestation to receive erythropoietin or placebo within 24 hours after birth.
191 sumed cardiac cause, early administration of erythropoietin plus standard therapy did not confer a be
193 stored with ECFCs and almost totally so with erythropoietin priming (control, 72% +/- 2%; ECFCPBS, 90
194 lighted its notable role in ECFC homing with erythropoietin priming (ECFCEPO, 147% +/- 14%, n = 4; EC
198 into fibroblast-like cells resembling native erythropoietin-producing cells located in the tubulointe
200 tudy aims to investigate the significance of erythropoietin-producing hepatocellular (Eph)A2 expressi
201 like kinase suppressor of Ras 1 (KSR1), EPH (erythropoietin-producing hepatocellular carcinoma) recep
204 Beyond the well-defined role of the Eph (erythropoietin-producing hepatocellular) receptor tyrosi
205 el of toll-like receptor 4 (TLR4), TLR2, and erythropoietin-producing hepatoma A2 (EphA2) expression
210 nontoxic doses of 5-azacytidine can restore erythropoietin production and ameliorate anemia in the s
211 age-related changes, organ function such as erythropoietin production in the kidney may become subop
214 on HIF-dependent transcriptional regulation, erythropoietin production, and cellular energy metabolis
215 by erythrocytosis with suppressed endogenous erythropoietin production, bone marrow panmyelosis, and
217 nts with acute-on-chronic liver failure, and erythropoietin promoted hepatic regeneration in animal s
218 te protein/peptide context, such as with the erythropoietin protein, a V3 polypeptide derived from HI
220 failing signal transduction at the homomeric erythropoietin receptor (EpoR) and at the heteromeric in
223 n) scaffold, that can systematically control erythropoietin receptor (EpoR) dimerization orientation
224 In this issue of Blood, Li et al show that erythropoietin receptor (Epor) expression marks the cent
225 L traptamers) that specifically activate the erythropoietin receptor (EPOR) in mouse cells to confer
228 (EPO) regulates erythropoiesis by binding to erythropoietin receptor (Epor) on erythroid progenitor c
229 und and unbound forms, the activation of the erythropoietin receptor (EPOR) was initially proposed to
230 ates growth hormone receptor (GHR-pY595) and erythropoietin receptor (EpoR-pY426) at 1.98 angstrom an
231 d property of all EMAs, to bind on the human erythropoietin receptor (hEPOR), is therefore exploited.
233 escribe four different rearrangements of the erythropoietin receptor gene EPOR in Philadelphia chromo
234 t-derived growth factor beta receptor or the erythropoietin receptor in cultured mouse cells, resulti
236 cal and suggests that studying modulation of erythropoietin receptor pathway may lead to strategies i
237 vates the 3 main myeloid cytokine receptors (erythropoietin receptor, granulocyte colony-stimulating
241 mice, erythropoietin levels were higher but erythropoietin-regulated genes were generally downregula
242 endent iron export regulated by hepcidin, d) erythropoietin regulation of erythropoiesis, and e) live
244 ion and clinical stages of PDR, suggest that erythropoietin represents an important growth factor fro
245 light on the molecular mechanisms underlying erythropoietin repression in kidney myofibroblasts and d
246 f ineffective erythropoiesis possibly due to erythropoietin resistance associated with iron deficienc
247 25 levels in the short term and may increase erythropoietin resistance in the long term among haemodi
250 shortened erythrocyte half-life, suppressed erythropoietin response to anemia, and inhibition of ery
256 emoglobin (Hb) response to recombinant human erythropoietin (rhEPO) therapy after hematopoietic cell
259 illegal administration of recombinant human erythropoietin (rHuEPO) among athletes is largely prefer
260 conformational state of 12 recombinant human erythropoietin (rHuEPO) therapeutic protein products; on
261 errin receptor (sTfR), hepcidin, serum iron, erythropoietin, serum folate, vitamin B-12, C-reactive p
262 lphaC mutations reduce homomeric (JAK2-JAK2) erythropoietin signaling and almost completely abrogate
263 These observations suggest that the altered erythropoietin signaling is focal and suggests that stud
264 find-me" signals from apoptotic cells induce erythropoietin signaling within macrophages to prime the
266 lation fingerprinting by comparing different Erythropoietin sources without the need for any sample p
267 erythroid lineage as a feedback mechanism of erythropoietin-stimulated erythropoiesis during iron/hem
268 6.88 mg/wk active control; P<0.001) and less erythropoietin-stimulating agent (median epoetin-equival
269 sferrin saturation, and intravenous iron and erythropoietin-stimulating agent usage as prespecified s
270 iron stores and reduces intravenous iron and erythropoietin-stimulating agent use while maintaining h
272 Administration boxed warning was issued for erythropoietin-stimulating agents (ESAs) regarding serio
274 gulated EPOR expression, hypersensitivity to erythropoietin stimulation, and heightened JAK-STAT acti
276 nts and an exaggerated response to exogenous erythropoietin sufficient to ameliorate the anemia.
277 The embryonic liver is the main site of erythropoietin synthesis, after which the kidney takes o
279 lpha1 type I collagen and PDGFRbeta, produce erythropoietin through HIF2alpha regulation but that pro
281 EGF, VEGF receptor 1 (VEGFR1), VEGFR2, Tie2, erythropoietin, transforming growth factor beta1, insuli
282 trajectories of progenitors from wild-type, erythropoietin-treated, and Flvcr1-deleted mice at singl
285 clinical trial of preterm infants, high-dose erythropoietin treatment within 42 hours after birth was
288 cident HF events, and each doubling of serum erythropoietin was associated with a 25% increased risk
289 iesis was shown by Leon Jacobson in 1957 and erythropoietin was eventually purified from the urine of
292 randomized, double-blind trial of high-dose erythropoietin, we assigned 941 infants who were born at
293 ions after the switch from recombinant human erythropoietin, whereas mean hemoglobin decreased in the
295 ntifying intact O-glycopeptides of the human erythropoietin with a total of 188 O-glycopeptide spectr
296 ulated expression of physiological levels of erythropoietin with a well-tolerated dose of the inducer
299 lobin occurred with elevations in endogenous erythropoietin within the range usually observed in the
300 tudy used a factorial design to test whether erythropoietin would fail to improve favorable outcomes